Lifecore Biomedical, Inc. (LFCR) – What Are Analysts Saying About This Stock?

Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) have earned a consensus rating of “Reduce” from the five research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $6.50.

LFCR has been the topic of several analyst reports. Weiss Ratings upgraded shares of Lifecore Biomedical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Barrington Research downgraded shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a report on Tuesday, September 29th. Zacks Research raised shares of Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Craig Hallum cut shares of Lifecore Biomedical from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Finally, William Blair downgraded shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research report on Monday, September 28th.

Institutional Trading of Lifecore Biomedical

Several large investors have recently made changes to their positions in LFCR. SG Americas Securities LLC bought a new position in shares of Lifecore Biomedical in the 1st quarter valued at approximately $64,000. Deutsche Bank AG acquired a new stake in Lifecore Biomedical in the 2nd quarter worth approximately $137,000. Bank of America Corp DE boosted its position in Lifecore Biomedical by 64.4% during the first quarter. Bank of America Corp DE now owns 43,298 shares of the company’s stock worth $161,000 after purchasing an additional 16,961 shares during the period. Bank of New York Mellon Corp bought a new stake in Lifecore Biomedical during the second quarter worth approximately $353,000. Finally, GSA Capital Partners LLP bought a new stake in Lifecore Biomedical during the second quarter worth approximately $462,000. Institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Stock Performance

Shares of NASDAQ LFCR opened at $6.40 on Friday. The stock has a market cap of $242.26 million, a price-to-earnings ratio of -5.98 and a beta of 0.98. The business has a 50 day simple moving average of $5.22 and a 200 day simple moving average of $5.04. Lifecore Biomedical has a 52 week low of $3.63 and a 52 week high of $8.98.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $34.17 million during the quarter, compared to analyst estimates of $34.18 million. On average, analysts predict that Lifecore Biomedical will post -1.02 EPS for the current year.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a contract development and manufacturing organization that provides development, formulation, aseptic filling, packaging and other manufacturing services for pharmaceutical and biopharmaceutical companies. The company specializes in complex sterile injectable products and supports customers from development through commercial production.

Lifecore has particular expertise in hyaluronic acid, a naturally occurring substance used in ophthalmic, orthopedic, aesthetic and other medical applications.